Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run

Written by Jonathan Ponciano for The Motley Fool->

The transaction involved the sale of 200,000 shares at a weighted average price of $6.24 per share on July 10.

This disposal reduced the insider's direct common stock holdings by 18%.

The activity was executed under a Rule 10b5-1 trading plan established on June 11, 2025.

Nagendran Sukumar, president and head of R&D at Taysha Gene Therapies, Inc. (NASDAQ:TSHA), sold 200,000 shares of common stock on July 10, 2026, for proceeds of $1.2 million, according to a recent SEC Form 4 filing.

Taysha Gene Therapies is a clinical-stage biotechnology company with a market capitalization of $1.60 billion, currently generating $7.50 million in TTM revenue while investing substantially in its gene therapy pipeline. The company leverages AAV vector technology as its core platform to develop differentiated therapeutic solutions for rare inherited CNS diseases, competing in a specialized segment of the biotechnology industry where clinical advancement and regulatory success are primary value drivers.

This sale ultimately seems like a standard scheduled cash-out given the underlying mechanics. The trade ran under a 10b5-1 plan Sukumar set more than a year ago, and even after selling, he holds 936,410 shares worth close to $6 million. When an R&D chief keeps a stake that size ahead of the company's biggest catalysts, it’s more likely that he's probably just diversifying and not doubting the science he's running.Operationally, Taysha last month reaffirmed FDA alignment on a BLA pathway for TSHA-102, its Rett syndrome gene therapy, including the pivotal REVEAL trial, which completed dosing of 17 patients last month and posted data showing early, durable treatment across all 12 pediatric, adolescent and adult patients. Meanwhile, the company’s $276.6 million cash balance funds operations into 2028, comfortably past those milestones.For long-term investors, the insider sale is a sideshow, and instead, the REVEAL trial and the BLA submission timeline are the events that decide whether the stock's 149% run was justified. After all, the company is still a good example of the risks in biotech, having struggled in the years since reaching an all-time high above $30 per share and still down some 80%.

Before you buy stock in Taysha Gene Therapies, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Taysha Gene Therapies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $395,679!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,805!*

Now, it’s worth noting Stock Advisor’s total average return is 929% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

*Stock Advisor returns as of July 12, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This data feed is not available at this time.